SLC5A2 and Stroke: Those in the group with prior MI or stroke had similar use of an ACE inhibitor or ARB at year 2 compared with those without MI or stroke (51.5% vs 48.9%; P = .12) but were more likely to be using an SGLT2 inhibitor at 2 years (7.5% vs 3.9%; P < .001) (eTable 2 in Supplement 2).